Related Experiment Video
Updated: Jul 6, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Use of statins in children].
L Tapia Ceballos1, B Picazo Angelín, C Ruiz García
1Servicio de Pediatría. Hospital Costa del Sol. Marbella. Málaga. España. leotapiaceb@hotmail.com
Anales De Pediatria (Barcelona, Spain : 2003)
|April 9, 2008
Summary
Statins, drugs inhibiting HMG-CoA reductase, are safe and effective for treating high cholesterol in children. These medications efficiently reduce total cholesterol and LDL-C levels, offering a beneficial treatment option for pediatric hypercholesterolemia.
Area of Science:
- Pharmacology
- Pediatric Endocrinology
Context:
- Hyperlipidemia treatment has evolved with statins, HMG-CoA reductase inhibitors.
- Statins are proven safe and effective in adults for managing high cholesterol.
- Pediatric hypercholesterolemia is a growing concern requiring effective treatment strategies.
Purpose:
- To evaluate the safety and efficacy of statin use in children for hypercholesterolemia.
- To review the available evidence on six specific statins used in pediatric populations.
Summary:
- Six statins (lovastatin, fluvastatin, pravastatin, simvastatin, atorvastatin, rosuvastatin) have been utilized in pediatric studies.
- Follow-up periods extended up to three years in some studies.
- Results indicate that statins are safe and effective in reducing total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in children.
Impact:
- Establishes statins as a viable and safe therapeutic option for pediatric hypercholesterolemia.
- Provides evidence supporting the long-term use of statins in managing cholesterol levels during childhood.
- Contributes to improved cardiovascular health outcomes for children with lipid disorders.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...